Obesity studies can look straightforward at the first feasibility review. A site treats patients with obesity, the investigator is interested, and the database appears large enough to support the proposed enrollment target. Then the protocol arrives. Prior medication exposure matters. Diabetes status matters. Screening requires several visits or outside assessments. Other metabolic studies are drawing from the same clinical population.
The right question for a sponsor or CRO is not simply how many patients a site can identify. It is how many people could reasonably move through this particular protocol, within the available enrollment window, without setting up a visit schedule the site or the participant cannot sustain. That distinction is especially important when evaluating obesity clinical trial sites in Florida.
Start with the exact population, not the diagnosis count
Obesity is a broad starting label. A protocol may narrow the population by body mass index, weight stability, prior or current anti-obesity medication, diabetes status, cardiovascular history, laboratory results or other characteristics. Two studies enrolling adults with obesity can reach very different groups of patients.
Ask the site to show how it moves from a distinct patient count to a protocol-relevant population. Which criteria can be assessed from current records? Which require physician review, a new test or a direct conversation with the patient? How current are the underlying height, weight and medication records? A historic diagnosis or an old weight should not automatically be treated as present-day eligibility.
WCR’s obesity and weight-management program describes a model connected to established primary-care and metabolic practices, with bilingual prescreening and study-specific feasibility. These relationships are useful entry points, but each proposed study still needs its own eligibility review.
Look at competition the way a potential participant would
A competing trial is not just another entry in a study database. It may be an offer from a neighboring clinic, another opportunity at the same practice or a program that attracts patients because its visit schedule appears more manageable. The patient has to choose whether research fits their life, and several studies may seek people with overlapping medical histories.
During site selection, ask which obesity, diabetes and cardiometabolic studies are currently recruiting locally and within the investigator’s own clinical network. Check whether the same physicians, coordinators or appointment slots are supporting those protocols. Public trial listings are a starting point, not a complete measure of local competition: advertised recruitment status and real operational demand can differ.
The practical output is a competition assessment tied to the proposed enrollment period. It should explain possible overlap in eligibility, where the study might be meaningfully different and what the site plans to do when multiple studies compete for the same candidate. A simple count of nearby trials cannot answer that by itself.
Test the route from a practice patient to a screening visit
Established physician relationships can shorten the distance between identifying a possible candidate and having an informed research conversation. They do not eliminate the work between those steps. The team still needs a suitable contact pathway, enough information for preliminary review, timely responses to questions and appointments that match the protocol.
A sponsor should ask who owns each handoff: initial review, approved outreach, medical record follow-up, clinical questions, screening scheduling and the decision to proceed. Where does an interested patient wait if outside records are missing? How are nonresponses recorded? Who follows up, and when? These details tell more about likely screening flow than a database screenshot.
WCR’s published obesity and weight-maintenance case study reports eight participants screened in less than one month, with all eight subsequently randomized. Those are outcomes from that specific Phase 3b study, not a general success rate or a promise for another protocol. Its operational lesson is more portable than the number: recruitment came through the investigator’s practice while staff coordinated ophthalmology assessments, nutrition services and lifestyle counseling.
Build one calendar for research and outside care
The scheduled research visit is not always the full participant commitment. Depending on the protocol, screening may involve fasting, laboratory tests, electrocardiography, body-composition assessments, questionnaires, imaging, ophthalmology appointments, nutritional counseling or other evaluations. Some services may occur at the research site; others may require outside providers.
Do not assume a capability is on-site because it is available through a referral arrangement. Ask where every assessment will happen, who schedules it, who pays the vendor, how results return to the investigator and which steps must be completed before randomization. A missing assessment can delay a candidate even when the research team has room on its own calendar.
Request a specimen schedule and a participant-facing appointment map, not just the protocol schedule of assessments. The map should show likely time away from work, travel between locations, preparation requirements and the time needed to recover from a long visit. Those are real participation considerations, not minor scheduling details.
Separate a fast first screening from repeatable capacity
Early screening is encouraging, but a first appointment can reflect a small group of candidates who were ready before activation. Sustainable enrollment depends on what happens after that group. Can the research team continue identifying and reviewing new candidates while completing baseline visits, safety assessments and follow-up for enrolled participants?
WCR’s separate Phase 3 obesity case study reports first screening two days after activation, followed by ongoing recruitment. It also describes outside appointment coordination. That case illustrates why activation-to-first-screening and month-by-month capacity should be assessed separately. A sponsor should not extrapolate a single early milestone into an expected monthly rate for a different study.
Ask for the number and types of open appointment slots, assigned clinical staff, investigator availability and vendor capacity during the actual recruitment months. Stress-test the schedule against an ordinary busy week. If multiple long visits land on the same day, which activity moves, and does that move stay within the protocol window?
Plan retention before the first consent conversation
Weight-management studies may require continued visits, medication accountability, symptom and adverse-event review, questionnaires or lifestyle-related tasks. The expected burden depends on the protocol. The relevant concern is not a stereotype about patients with obesity; it is whether the study’s real requirements are understandable and achievable for the people being invited.
Discuss costs and practical support early. Participants may need transportation, time away from work, childcare arrangements or repeated fasting appointments. Available reimbursement, stipends or travel assistance must match the approved study arrangements; a site cannot promise support that the sponsor has not authorized.
The FDA’s September 2025 E6(R3) Good Clinical Practice guidance asks sponsors to consider operational feasibility and avoid unnecessary complexity or burden for participants and investigators. A thoughtful feasibility process makes the burden visible before enrollment begins. Ask how visit instructions are explained, who responds to scheduling conflicts and how the team notices a participant drifting out of contact.
A useful sponsor checklist for obesity-site feasibility
Before assigning an enrollment target, request clear answers to the following questions. The purpose is not to create a longer feasibility questionnaire. It is to identify the assumptions that will determine whether a site can execute this particular obesity protocol.
- Population: Which inclusion and exclusion criteria can be supported by current distinct-patient records, and which remain unknown?
- Competition: What other studies could reach the same candidates during the planned enrollment window?
- Patient pathway: Who owns prescreening, appropriate outreach, records, medical review and scheduling?
- Visit burden: Which assessments happen on-site, which require outside coordination, and how many separate trips may be needed?
- Capacity: What staffing, investigator time and vendor appointments are available after the first screening group?
- Retention: How will participants receive clear expectations, approved practical support and timely follow-up?
- Forecast: What evidence supports the screening and randomization estimate, and what would cause the team to revise it?
Select the operating plan, not only the patient pool
A credible obesity trial site is able to explain both sides of feasibility: the people it may reach and the work required to support them. It is reasonable for the answer to include uncertainties. A site that distinguishes documented facts, study-specific assumptions and unresolved logistics gives the sponsor a better basis for planning than one that commits to a number without showing its path.
WCR works across South Florida and Puerto Rico through one coordinated research network. A proposed Florida obesity protocol should be evaluated for its particular investigator fit, practice relationships, capacity and visit requirements, rather than by applying results from another study. Share the intended population, assessment schedule and enrollment window through our study inquiry form to start that discussion.